Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes.

Turcotte LM, Cao Q, Cooley SA, Curtsinger J, Holtan SG, Luo X, Yingst A, Weisdorf DJ, Blazar BR, Miller JS, Wagner JE, Verneris MR.

Biol Blood Marrow Transplant. 2019 Jan 6. pii: S1083-8791(19)30006-0. doi: 10.1016/j.bbmt.2019.01.003. [Epub ahead of print]

PMID:
30625388
2.

Fecundity for free? Enhanced oviposition in longevous populations of Drosophila melanogaster.

Curtsinger JW.

Biogerontology. 2019 Jan 3. doi: 10.1007/s10522-018-09791-1. [Epub ahead of print]

PMID:
30603852
3.

Reproductive homeostasis and senescence in Drosophila melanogaster.

Curtsinger JW.

J Gerontol A Biol Sci Med Sci. 2018 Dec 6. doi: 10.1093/gerona/gly274. [Epub ahead of print]

PMID:
30521013
4.

Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples.

Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Scott BL, Blazar BR, Weisdorf DJ.

Br J Haematol. 2018 Sep;182(6):887-894. doi: 10.1111/bjh.15492. Epub 2018 Jul 13.

PMID:
30004111
5.

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.

Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, Curtsinger J, Warlick E, Spellman SR, Blazar BR, Weisdorf DJ, Cooley S, Vallera DA, Önfelt B, Miller JS.

Blood Adv. 2018 Jun 26;2(12):1459-1469. doi: 10.1182/bloodadvances.2017012369.

6.

Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.

Sarhan D, Hippen KL, Lemire A, Hying S, Luo X, Lenvik T, Curtsinger J, Davis Z, Zhang B, Cooley S, Cichocki F, Blazar BR, Miller JS.

Cancer Immunol Res. 2018 Jul;6(7):766-775. doi: 10.1158/2326-6066.CIR-17-0498. Epub 2018 May 21.

PMID:
29784636
7.

Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect.

Rashidi A, Ebadi M, Said B, Cao Q, Shanley R, Curtsinger J, Bejanyan N, Warlick ED, Green JS, Brunstein CG, Miller JS, Weisdorf DJ.

Am J Hematol. 2018 May 14. doi: 10.1002/ajh.25141. [Epub ahead of print]

PMID:
29756385
8.

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.

Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, Mehta RS, Warlick E, Cooley SA, Blazar BR, Miller JS, Weisdorf D, Wagner JE, Verneris MR.

Blood Adv. 2018 Apr 24;2(8):909-922. doi: 10.1182/bloodadvances.2017014464.

9.

A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1581-1589. doi: 10.1016/j.bbmt.2018.03.019. Epub 2018 Mar 27.

PMID:
29597002
10.

Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution.

Williams SM, Sumstad D, Kadidlo D, Curtsinger J, Luo X, Miller JS, McKenna DH Jr.

Transfusion. 2018 Jun;58(6):1458-1467. doi: 10.1111/trf.14564. Epub 2018 Mar 12.

PMID:
29532488
11.

Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples.

Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Miller JS, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2018 Aug;53(8):1069-1071. doi: 10.1038/s41409-018-0127-3. Epub 2018 Mar 7. No abstract available.

PMID:
29515246
12.

Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy.

de Witte MA, Sarhan D, Davis Z, Felices M, Vallera DA, Hinderlie P, Curtsinger J, Cooley S, Wagner J, Kuball J, Miller JS.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1152-1162. doi: 10.1016/j.bbmt.2018.02.023. Epub 2018 Mar 2.

PMID:
29505821
13.

Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.

Bachanova V, Sarhan D, DeFor TE, Cooley S, Panoskaltsis-Mortari A, Blazar BR, Curtsinger JM, Burns L, Weisdorf DJ, Miller JS.

Cancer Immunol Immunother. 2018 Mar;67(3):483-494. doi: 10.1007/s00262-017-2100-1. Epub 2017 Dec 7.

14.

Fewer Circulating Natural Killer Cells 28 Days After Double Cord Blood Transplantation Predicts Inferior Survival and IL-15 Response.

Bergerson RJ, Williams R, Wang H, Shanley R, Colbenson G, Kerber A, Cooley S, Curtsinger J, Felices M, Miller JS, Verneris MR.

Blood Adv. 2016 Dec 27;1(3):208-218. doi: 10.1182/bloodadvances.2016000158. Epub 2016 Oct 30.

15.

Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies.

Touma W, Brunstein CG, Cao Q, Miller JS, Curtsinger J, Verneris MR, Bachanova V.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1925-1931. doi: 10.1016/j.bbmt.2017.07.008. Epub 2017 Jul 17.

16.

Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.

McKenna DH Jr, Sumstad D, Kadidlo DM, Batdorf B, Lord CJ, Merkel SC, Koellner CM, Curtsinger JM, June CH, Riley JL, Levine BL, Miller JS, Brunstein CG, Wagner JE, Blazar BR, Hippen KL.

Cytotherapy. 2017 Feb;19(2):250-262. doi: 10.1016/j.jcyt.2016.10.011. Epub 2016 Nov 22.

17.

Retired flies, hidden plateaus, and the evolution of senescence in Drosophila melanogaster.

Curtsinger JW.

Evolution. 2016 Jun;70(6):1297-306. doi: 10.1111/evo.12946. Epub 2016 Jun 1.

PMID:
27166620
18.

Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.

Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar BR, Wagner JE.

Blood. 2016 Feb 25;127(8):1044-51. doi: 10.1182/blood-2015-06-653667. Epub 2015 Nov 12.

19.

The Retired Fly: Detecting Life History Transition in Individual Drosophila melanogaster Females.

Curtsinger JW.

J Gerontol A Biol Sci Med Sci. 2015 Dec;70(12):1455-60. doi: 10.1093/gerona/glv122. Epub 2015 Sep 10.

PMID:
26359246
20.

On the analysis and interpretation of late-life fecundity in Drosophila melanogaster.

Curtsinger JW.

Exp Gerontol. 2015 Dec;72:22-8. doi: 10.1016/j.exger.2015.08.020. Epub 2015 Sep 5.

PMID:
26344177
21.

Postthaw characterization of umbilical cord blood: markers of storage lesion.

Hubel A, Spindler R, Curtsinger JM, Lindgren B, Wiederoder S, McKenna DH.

Transfusion. 2015 May;55(5):1033-9. doi: 10.1111/trf.12971. Epub 2014 Dec 19.

22.

Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.

Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, Tolar J.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1252-7. doi: 10.1016/j.bbmt.2014.05.004. Epub 2014 May 9.

23.

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS.

Blood. 2014 Jun 19;123(25):3855-63. doi: 10.1182/blood-2013-10-532531. Epub 2014 Apr 9.

24.

Functional NK cell repertoires are maintained through IL-2Rα and Fas ligand.

Felices M, Lenvik TR, Ankarlo DE, Foley B, Curtsinger J, Luo X, Blazar BR, Anderson SK, Miller JS.

J Immunol. 2014 Apr 15;192(8):3889-97. doi: 10.4049/jimmunol.1302601. Epub 2014 Mar 14.

25.

Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression.

Sawitzki B, Brunstein C, Meisel C, Schumann J, Vogt K, Appelt C, Curtsinger JM, Verneris MR, Miller JS, Wagner JE, Blazar BR.

Biol Blood Marrow Transplant. 2014 Feb;20(2):173-82. doi: 10.1016/j.bbmt.2013.10.022. Epub 2013 Nov 1.

26.

Late-life fecundity plateaus in Drosophila melanogaster can be explained by variation in reproductive life spans.

Curtsinger JW.

Exp Gerontol. 2013 Nov;48(11):1338-42. doi: 10.1016/j.exger.2013.08.016. Epub 2013 Sep 5.

PMID:
24012993
27.

The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity.

Wang Y, Shaked I, Stanford SM, Zhou W, Curtsinger JM, Mikulski Z, Shaheen ZR, Cheng G, Sawatzke K, Campbell AM, Auger JL, Bilgic H, Shoyama FM, Schmeling DO, Balfour HH Jr, Hasegawa K, Chan AC, Corbett JA, Binstadt BA, Mescher MF, Ley K, Bottini N, Peterson EJ.

Immunity. 2013 Jul 25;39(1):111-22. doi: 10.1016/j.immuni.2013.06.013. Epub 2013 Jul 18.

28.

Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation.

Brunstein CG, Blazar BR, Miller JS, Cao Q, Hippen KL, McKenna DH, Curtsinger J, McGlave PB, Wagner JE.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1271-3. doi: 10.1016/j.bbmt.2013.06.004. Epub 2013 Jun 25. No abstract available.

29.

Cytotoxic T lymphocytes and vaccine development 2013.

Xiao Z, Klonowski K, Yang H, Curtsinger J.

Biomed Res Int. 2013;2013:865314. doi: 10.1155/2013/865314. Epub 2013 Feb 4. No abstract available.

30.

Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma.

Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, Dudek AZ.

Am J Clin Oncol. 2014 Jun;37(3):261-5. doi: 10.1097/COC.0b013e318277d5c8.

31.

Pleiotropy and life history evolution in Drosophila melanogaster: uncoupling life span and early fecundity.

Khazaeli AA, Curtsinger JW.

J Gerontol A Biol Sci Med Sci. 2013 May;68(5):546-53. doi: 10.1093/gerona/gls226. Epub 2012 Nov 16.

32.

Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen.

Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Anasetti C, Weisdorf D, Miller JS.

J Immunol. 2012 Nov 15;189(10):5082-8. doi: 10.4049/jimmunol.1201964. Epub 2012 Oct 17.

33.

Autocrine IFN-γ promotes naive CD8 T cell differentiation and synergizes with IFN-α to stimulate strong function.

Curtsinger JM, Agarwal P, Lins DC, Mescher MF.

J Immunol. 2012 Jul 15;189(2):659-68. doi: 10.4049/jimmunol.1102727. Epub 2012 Jun 15.

34.

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function.

Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, Lopez-Vergès S, Lanier LL, Weisdorf D, Miller JS.

Blood. 2012 Mar 15;119(11):2665-74. doi: 10.1182/blood-2011-10-386995. Epub 2011 Dec 16.

35.

T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.

Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J.

Biol Blood Marrow Transplant. 2012 Jun;18(6):937-43. doi: 10.1016/j.bbmt.2011.11.024. Epub 2011 Dec 7.

36.

Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Hippen KL, Bucher C, Schirm DK, Bearl AM, Brender T, Mink KA, Waggie KS, Peffault de Latour R, Janin A, Curtsinger JM, Dillon SR, Miller JS, Socie G, Blazar BR.

Blood. 2012 Jan 12;119(2):619-28. doi: 10.1182/blood-2011-07-368027. Epub 2011 Nov 10.

37.

NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions.

Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Weisdorf DJ, Miller JS.

Blood. 2011 Sep 8;118(10):2784-92. doi: 10.1182/blood-2011-04-347070. Epub 2011 Jul 14.

38.

Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma.

Henson MS, Curtsinger JM, Larson VS, Klausner JS, Modiano JF, Mescher MF, Miller JS.

Vet Comp Oncol. 2011 Jun;9(2):95-105. doi: 10.1111/j.1476-5829.2010.00234.x. Epub 2010 Aug 16.

PMID:
21569195
39.

Cytotoxic T lymphocytes and vaccine development 2011.

Xiao Z, Klonowski K, Yang H, Curtsinger J.

J Biomed Biotechnol. 2011;2011:756864. doi: 10.1155/2011/756864. Epub 2012 May 6. No abstract available.

40.

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE.

Blood. 2011 Jan 20;117(3):1061-70. doi: 10.1182/blood-2010-07-293795. Epub 2010 Oct 15.

41.

Life history variation in an artificially selected population of Drosophila melanogaster: pleiotropy, superflies, and age-specific adaptation.

Khazaeli AA, Curtsinger JW.

Evolution. 2010 Dec;64(12):3409-16. doi: 10.1111/j.1558-5646.2010.01139.x. Epub 2010 Oct 18.

PMID:
20874737
42.

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS.

Cytotherapy. 2011 Jan;13(1):98-107. doi: 10.3109/14653249.2010.515582. Epub 2010 Sep 20.

43.

Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers.

Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS.

Cancer Immunol Immunother. 2010 Dec;59(12):1877-1884. doi: 10.1007/s00262-010-0914-1. Epub 2010 Sep 5.

44.

Allogeneic natural killer cells for refractory lymphoma.

Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS.

Cancer Immunol Immunother. 2010 Nov;59(11):1739-44. doi: 10.1007/s00262-010-0896-z. Epub 2010 Aug 3.

45.

Inflammatory cytokines as a third signal for T cell activation.

Curtsinger JM, Mescher MF.

Curr Opin Immunol. 2010 Jun;22(3):333-40. doi: 10.1016/j.coi.2010.02.013. Epub 2010 Apr 2. Review.

46.

Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory.

Agarwal P, Raghavan A, Nandiwada SL, Curtsinger JM, Bohjanen PR, Mueller DL, Mescher MF.

J Immunol. 2009 Aug 1;183(3):1695-704. doi: 10.4049/jimmunol.0900592. Epub 2009 Jul 10.

47.

Programming for CD8 T cell memory development requires IL-12 or type I IFN.

Xiao Z, Casey KA, Jameson SC, Curtsinger JM, Mescher MF.

J Immunol. 2009 Mar 1;182(5):2786-94. doi: 10.4049/jimmunol.0803484.

48.

Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.

Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS.

Am J Clin Oncol. 2008 Apr;31(2):173-81. doi: 10.1097/COC.0b013e3181573e6b.

PMID:
18391603
49.

Genes, aging, and prospects for extended life span.

Curtsinger JW.

Minn Med. 2007 Oct;90(10):41-4.

PMID:
18038742
50.

Supplemental Content

Loading ...
Support Center